Research collaboration between Microbot Medical, Washington University School of Medicine

Research collaboration between Microbot Medical, Washington University School of Medicine

Designed to prevent obstruction in cerebrospinal fluid catheters, the study will evaluate a self-cleaning shunt device.

Subscribe
February 13, 2017
Manufacturing Group
Design/Engineering Devices/Implants/Equipment

Hingham, Massachusetts – Microbot Medical Inc., a medical device company specializing in the design and development of transformational micro-robotic medical technologies, announced that it has entered into a research collaboration agreement with Washington University School of Medicine, a leading academic institution based in St. Louis, Missouri, to determine the safety and effectiveness of the Microbot Medical self-cleaning shunt (SCS), a device which is designed to prevent obstruction in the cerebrospinal fluid (CSF) catheters implanted in the ventricle of the brain of patients who suffer from hydrocephalus or normal pressure hydrocephalus (NPH).

Hydrocephalus is a condition which causes an excessive accumulation of fluid in the brain and effects one out of every 500 infants born in the United States alone every year while NPH is a condition that typically develops over time and effects the elderly population. The primary objective of these pre-clinical studies is to determine the safety and effectiveness of the company’s SCS device to prevent obstruction in CSF catheters in clinically relevant in vivo studies.

The principal investigators (PI) for the studies are James Patterson McAllister, PhD, a professor of neurology at Washington University School of Medicine and St. Louis Children’s Hospital, and David D. Limbrick, Jr., MD, PhD, professor and chief of pediatric neurosurgery at St. Louis Children’s Hospital. McAllister is a leading authority in the field of research aimed at identifying clinical treatments for hydrocephalus, and for the last 30 years his laboratory has maintained a comprehensive interdisciplinary translational research program whose goal is to improve clinical treatments for hydrocephalus. Limbrick focuses on treating children with neurological diseases, including hydrocephalus, and he has been recognized on The Best Doctors in America list.

“I can attest to the fact that surgical interventions for the treatment of hydrocephalus have not improved outcomes as much as expected and the major obstacle to progress is the failure to prevent shunt obstruction.  The studies we will be conducting with Microbot Medical are specifically intended to develop and test new approaches to solve this problem,” McAllister commented. “Our research group at Washington University is well positioned to partner with Microbot Medical in this endeavor as we have become one of the main hydrocephalus clinical and experimental research centers in the world.”

Concurrently, Carolyn Harris, PhD at Wayne State University (WSU) in Detroit, Michigan, will run an in vitro study of the company’s SCS device. The main objective of this study is to test and finalize the design of Microbot’s SCS, using Harris’ bio-reactor system that mimics human brain tissue three-dimensionally.  Harris is nationally and internationally recognized as an expert in hydrocephalus due to her comprehension of the pathophysiology of the disorder and her investigation into shunt obstruction and shunt infection utilizing unique model systems. The Harris laboratory studies hydrocephalus with a prudent focus on bioengineering strategies that could improve treatment.

“This is an exciting development milestone in continuing our efforts and progression to validate the safety and effectiveness of our self-cleaning shunt device,” comments Harel Gadot, CEO, president, and chairman. “We are addressing a large unmet need in this market and our collaboration with these leading academic institutions will allow us to validate our technology, and as such will allow us to transform any technology currently on the market, a market which really has not seen any major advancements since the 1950s. The study is being administered by some of the leading hydrocephalus clinicians and scientists in the world and we look forward to sharing the findings as we seek to improve and extend the quality of life for those suffering from hydrocephalus and normal pressure hydrocephalus.”

About Microbot Medical Inc.
Microbot was founded in 2010 and became a NASDAQ listed company on November 28, 2016. The Company specializes in transformational micro-robotic medical technologies leveraging the natural and artificial lumens within the human body. Microbot’s current platforms, ViRob and TipCAT, are comprised of two highly advanced micro-robotic technologies, from which the Company is currently developing its first two product candidates: the Self Cleaning Shunt, or SCS, for the treatment of hydrocephalus and Normal Pressure Hydrocephalus, or NPH; and a self-propelling, semi-disposable endoscope that is being developed initially for use in colonoscopy procedures.

The ViRob technology is a revolutionary autonomous crawling micro-robot which can be controlled remotely or within the body.  Its miniature dimensions allow it to navigate and crawl in different spaces within the human body, including blood vessels, the digestive tract and the respiratory system.  Its unique structure gives it the ability to move in tight spaces and curved passages as well as the ability to remain within the human body for prolonged time.

TipCAT is a transformational self-propelled, flexible, and semi-disposable endoscope providing see & treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract.  Its locomotion mechanism is perfectly suitable to navigate and crawl through natural & artificial tubular lumens, applying the minimal necessary pressure to achieve the adequate friction required for gentle, fast, and safe advancement within the human body.

About Washington University School of Medicine
Washington University School of Medicine’s 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation, currently ranked sixth in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.

Source: Microbot Medical